Financings In Brief: Sepracor
Executive Summary
Sepracor: Proposes new issue of $75 mil. of convertible subordinated debentures due 2002. The debentures will be convertible into common stock at a price to be determined. Proceeds from the sale will be used primarily for ongoing clinical and preclinical trials of the separation technologies company's Improved Chemical Entity pharmaceuticals...
Sepracor: Proposes new issue of $75 mil. of convertible subordinated debentures due 2002. The debentures will be convertible into common stock at a price to be determined. Proceeds from the sale will be used primarily for ongoing clinical and preclinical trials of the separation technologies company's Improved Chemical Entity pharmaceuticals.... |